Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1985 1
1987 2
1991 2
2008 1
2011 1
2012 3
2013 5
2014 1
2015 1
2016 2
2017 2
2018 4
2019 7
2020 7
2021 3
2023 1
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer.
Perets R, Bar J, Rasco DW, Ahn MJ, Yoh K, Kim DW, Nagrial A, Satouchi M, Lee DH, Spigel DR, Kotasek D, Gutierrez M, Niu J, Siddiqi S, Li X, Cyrus J, Chackerian A, Chain A, Altura RA, Cho BC. Perets R, et al. Among authors: chain a. Ann Oncol. 2021 Mar;32(3):395-403. doi: 10.1016/j.annonc.2020.11.020. Epub 2020 Dec 2. Ann Oncol. 2021. PMID: 33276076 Free article. Clinical Trial.
Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110.
Clarke DF, Mirochnick M, Acosta EP, Capparelli E, Chain A, Teppler H, Smith B, Lommerse J; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1110 Study Team. Clarke DF, et al. Among authors: chain a. J Acquir Immune Defic Syndr. 2019 Dec 1;82(4):392-398. doi: 10.1097/QAI.0000000000002149. J Acquir Immune Defic Syndr. 2019. PMID: 31658182 Free PMC article.
Immunogenicity of pembrolizumab in patients with advanced tumors.
van Vugt MJH, Stone JA, De Greef RHJMM, Snyder ES, Lipka L, Turner DC, Chain A, Lala M, Li M, Robey SH, Kondic AG, De Alwis D, Mayawala K, Jain L, Freshwater T. van Vugt MJH, et al. Among authors: chain a. J Immunother Cancer. 2019 Aug 8;7(1):212. doi: 10.1186/s40425-019-0663-4. J Immunother Cancer. 2019. PMID: 31395089 Free PMC article.
Translating QT interval prolongation from conscious dogs to humans.
Dubois VF, Smania G, Yu H, Graf R, Chain AS, Danhof M, Della Pasqua O; Cardiovascular Safety Project Team; TI Pharma PKPD Platform. Dubois VF, et al. Among authors: chain as. Br J Clin Pharmacol. 2017 Feb;83(2):349-362. doi: 10.1111/bcp.13123. Epub 2016 Oct 29. Br J Clin Pharmacol. 2017. PMID: 27614058 Free PMC article.
Combining an in silico proarrhythmic risk assay with a tPKPD model to predict QTc interval prolongation in the anesthetized guinea pig assay.
Morissette P, Polak S, Chain A, Zhai J, Imredy JP, Wildey MJ, Travis J, Fitzgerald K, Fanelli P, Passini E, Rodriguez B, Sannajust F, Regan C. Morissette P, et al. Among authors: chain a. Toxicol Appl Pharmacol. 2020 Mar 1;390:114883. doi: 10.1016/j.taap.2020.114883. Epub 2020 Jan 23. Toxicol Appl Pharmacol. 2020. PMID: 31981640 Free PMC article.
Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling.
Marathe DD, Jauslin PM, Kleijn HJ, de Miranda Silva C, Chain A, Bateman T, Shaw PM, Abraham AK, Kauh EA, Liu Y, Perini RF, de Alwis DP, Jain L. Marathe DD, et al. Among authors: chain a. CPT Pharmacometrics Syst Pharmacol. 2023 Oct;12(10):1499-1510. doi: 10.1002/psp4.13028. Epub 2023 Aug 28. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37596839 Free PMC article.
37 results